FAF technology encouraging in evaluating AMD, study finds

Article

Results of a recent clinical study provide promising evidence of the value of ultra-widefield fundus autofluorescence (FAF) imaging in the evaluation of age-related macular degernation (AMD)

Results of a recent clinical study provide promising evidence of the value of ultra-widefield fundus autofluorescence (FAF) imaging in the evaluation of age-related macular degeneration (AMD), according to lead investigator Dr SriniVas Sadda, MD, who presented the findings of the study at the annual meeting of the American Society of Retina Specialists.

In a study using FAF imaging technology (200Tx [formerly the P200MAAF multi-wavelength scanning laser ophthalmoscope], Optos), peripheral FAF abnormalities were found in 77% of eyes in the series, especially in those with retinal degenerations, inflammation, and AMD.

Using the images, 174 eyes showed peripheral changes outside the central pole area of the retina, the area viewed using standard narrow-field, 30° field of view imaging technology. The findings demonstrated that peripheral FAF abnormalities often correlate with areas of retinal pigment epithelium disturbance. Also, when correlation occurs, the abnormalities often appear more striking on FAF imaging than on the pseudocolor images due to better contrast, according to Dr Sadda, associate Professor of Ophthalmology and director at the Medical Retina Unit, Ophthalmic Imaging Unit, and the Doheny Image Reading Center at the Doheny Eye Institute, University of Southern California, Los Angeles.

"The significance of these findings still needs to be defined and requires further study," Dr Sadda said. "However, the evaluation of peripheral FAF abnormalities may aid in diagnosis and provide new insights into disease pathogenesis. This study follows the recently published results from the Reykjavik/Moorfields study and adds to the growing body of evidence of the importance of studying the periphery of the retina in the diagnosis and management of AMD."

The retrospective analysis reviewed the records of all patients referred to the Doheny Eye Institute imaging unit for FAF imaging who had widefield images (200CAF or 200Tx, Optos) obtained over a 6-month period. The research team collected widefield and non-widefield FAF images obtained at the same visit as well as demographic data, including disease diagnosis.

All widefield images were evaluated for the presence of FAF abnormalities, defined as increased or decreased, beyond the central 30°. The frequency of abnormalities was computed and FAF abnormalities within disease categories were scrutinized for characteristic patterns.

The analysis included 225 eyes of 122 patients with ultra-widefield imaging. In all, 174 eyes (77%) had abnormal peripheral FAF studies. This included 100% of the eyes with a diagnosis of ocular tumors (n = 6) or retinal degenerations (n = 31) and 90% of those with inflammatory or infectious retinal diseases diagnosed (n = 54). The analysis also revealed that 76% of eyes with AMD (n = 34) and 63% of those with miscellaneous eye diseases (n = 45) had abnormal peripheral FAF imaging, as did 36% (n = 4) of the eyes with central serous chorioretinopathy.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.